News|Articles|October 31, 2024
WCG Randomized 1,600 Participants for RSV Vaccine Trial
Author(s)WCG Clinical
A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
Trending on Applied Clinical Trials Online
1
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
2
Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value
3
ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion
4
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
5